Matches in SemOpenAlex for { <https://semopenalex.org/work/W4225562495> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W4225562495 endingPage "W4" @default.
- W4225562495 startingPage "W3" @default.
- W4225562495 abstract "LettersJanuary 2022Sodium–Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular DiseaseMei Qiu, MSMei Qiu, MSDepartment of General Medicine, Shenzhen Longhua District Central Hospital, Shenzhen, ChinaSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L21-0706 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:One of the main conclusions that Patorno and colleagues (1) draw is that there were no large differences between SGLT2 inhibitors and GLP-1 RAs in the risk for MI or stroke among patients with T2D with and without CVD. I believe that this conclusion is inconsistent with the findings revealed in Figure 2 of their article (1).As shown in Figure 2, compared with GLP-1 RAs, SGLT2 inhibitors were significantly associated with a reduced risk for primary cardiovascular outcomes (defined as a composite of hospitalization for either MI or stroke) in patients with T2D with CVD (hazard ...References1. Patorno E, Htoo PT, Glynn RJ, et al. Sodium–glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists and the risk for cardiovascular outcomes in routine care patients with diabetes across categories of cardiovascular disease. Ann Intern Med. 2021;174:1528-41. [PMID: 34570599] doi:10.7326/M21-0893 LinkGoogle Scholar2. Patorno E, Pawar A, Bessette LG, et al. Comparative effectiveness and safety of sodium-glucose cotransporter 2 inhibitors versus glucagon-like peptide 1 receptor agonists in older adults. Diabetes Care. 2021;44:826-35. [PMID: 33495295] doi:10.2337/dc20-1464 CrossrefMedlineGoogle Scholar3. Lugner M, Sattar N, Miftaraj M, et al. Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study. Cardiovasc Diabetol. 2021;20:67. [PMID: 33752680] doi:10.1186/s12933-021-01258-x CrossrefMedlineGoogle Scholar4. Longato E, Di Camillo, Sparacino G, et al. Cardiovascular outcomes of type 2 diabetic patients treated with SGLT-2 inhibitors versus GLP-1 receptor agonists in real-life. BMJ Open Diabetes Res Care. 2020;8. [PMID: 32591373] doi:10.1136/bmjdrc-2020-001451 CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Department of General Medicine, Shenzhen Longhua District Central Hospital, Shenzhen, ChinaDisclosures: The author has reported no disclosures of interest. The form can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=L21-0706. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoSodium–Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease Elisabetta Patorno , Phyo T. Htoo , Robert J. Glynn , Sebastian Schneeweiss , Deborah J. Wexler , Ajinkya Pawar , Lily G. Bessette , Kristyn Chin , Brendan M. Everett , and Seoyoung C. Kim Sodium–Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease Lurit Bepo , Anil N. Makam , and Oanh Kieu Nguyen Sodium–Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease Elisabetta Patorno , Phyo T. Htoo , Brendan M. Everett , and Seoyoung C. Kim Sodium–Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease Elisabetta Patorno , Phyo T. Htoo , Robert J. Glynn , Sebastian Schneeweiss , Deborah J. Wexler , Ajinkya Pawar , Lily G. Bessette , Kristyn Chin , Brendan M. Everett , and Seoyoung C. Kim Metrics January 2022Volume 175, Issue 1Page: W3-W4KeywordsCardiovascular diseasesCohort studiesDrugsHeart failureHemorrhagic strokeHospital medicineIschemic strokeMortalityMyocardial infarctionPopulation statistics ePublished: 18 January 2022 Issue Published: January 2022 Copyright & PermissionsCopyright © 2022 by American College of Physicians. All Rights Reserved.PDF downloadLoading ..." @default.
- W4225562495 created "2022-05-05" @default.
- W4225562495 creator A5050298481 @default.
- W4225562495 date "2022-01-01" @default.
- W4225562495 modified "2023-10-14" @default.
- W4225562495 title "Sodium–Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease" @default.
- W4225562495 doi "https://doi.org/10.7326/l21-0706" @default.
- W4225562495 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35038402" @default.
- W4225562495 hasPublicationYear "2022" @default.
- W4225562495 type Work @default.
- W4225562495 citedByCount "0" @default.
- W4225562495 crossrefType "journal-article" @default.
- W4225562495 hasAuthorship W4225562495A5050298481 @default.
- W4225562495 hasConcept C126322002 @default.
- W4225562495 hasConcept C127413603 @default.
- W4225562495 hasConcept C134018914 @default.
- W4225562495 hasConcept C170493617 @default.
- W4225562495 hasConcept C178790620 @default.
- W4225562495 hasConcept C185280430 @default.
- W4225562495 hasConcept C185592680 @default.
- W4225562495 hasConcept C188053792 @default.
- W4225562495 hasConcept C207103383 @default.
- W4225562495 hasConcept C2776398474 @default.
- W4225562495 hasConcept C2777180221 @default.
- W4225562495 hasConcept C2778938600 @default.
- W4225562495 hasConcept C2779134260 @default.
- W4225562495 hasConcept C2780645631 @default.
- W4225562495 hasConcept C44249647 @default.
- W4225562495 hasConcept C537181965 @default.
- W4225562495 hasConcept C555293320 @default.
- W4225562495 hasConcept C71924100 @default.
- W4225562495 hasConcept C78519656 @default.
- W4225562495 hasConceptScore W4225562495C126322002 @default.
- W4225562495 hasConceptScore W4225562495C127413603 @default.
- W4225562495 hasConceptScore W4225562495C134018914 @default.
- W4225562495 hasConceptScore W4225562495C170493617 @default.
- W4225562495 hasConceptScore W4225562495C178790620 @default.
- W4225562495 hasConceptScore W4225562495C185280430 @default.
- W4225562495 hasConceptScore W4225562495C185592680 @default.
- W4225562495 hasConceptScore W4225562495C188053792 @default.
- W4225562495 hasConceptScore W4225562495C207103383 @default.
- W4225562495 hasConceptScore W4225562495C2776398474 @default.
- W4225562495 hasConceptScore W4225562495C2777180221 @default.
- W4225562495 hasConceptScore W4225562495C2778938600 @default.
- W4225562495 hasConceptScore W4225562495C2779134260 @default.
- W4225562495 hasConceptScore W4225562495C2780645631 @default.
- W4225562495 hasConceptScore W4225562495C44249647 @default.
- W4225562495 hasConceptScore W4225562495C537181965 @default.
- W4225562495 hasConceptScore W4225562495C555293320 @default.
- W4225562495 hasConceptScore W4225562495C71924100 @default.
- W4225562495 hasConceptScore W4225562495C78519656 @default.
- W4225562495 hasIssue "1" @default.
- W4225562495 hasLocation W42255624951 @default.
- W4225562495 hasLocation W42255624952 @default.
- W4225562495 hasOpenAccess W4225562495 @default.
- W4225562495 hasPrimaryLocation W42255624951 @default.
- W4225562495 hasRelatedWork W1998141110 @default.
- W4225562495 hasRelatedWork W2013015015 @default.
- W4225562495 hasRelatedWork W2013336037 @default.
- W4225562495 hasRelatedWork W2126965169 @default.
- W4225562495 hasRelatedWork W2127396703 @default.
- W4225562495 hasRelatedWork W2133314507 @default.
- W4225562495 hasRelatedWork W2339230445 @default.
- W4225562495 hasRelatedWork W2411384485 @default.
- W4225562495 hasRelatedWork W2810103495 @default.
- W4225562495 hasRelatedWork W2901300568 @default.
- W4225562495 hasVolume "175" @default.
- W4225562495 isParatext "false" @default.
- W4225562495 isRetracted "false" @default.
- W4225562495 workType "article" @default.